These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 27087007)

  • 1. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
    Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.
    Nelsen LM; Cockle SM; Gunsoy NB; Jones P; Albers FC; Bradford ES; Mullerova H
    J Asthma; 2020 Sep; 57(9):1006-1016. PubMed ID: 31251094
    [No Abstract]   [Full Text] [Related]  

  • 10. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
    Albers FC; Papi A; Taillé C; Bratton DJ; Bradford ES; Yancey SW; Kwon N
    Respir Res; 2019 Jul; 20(1):169. PubMed ID: 31362741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
    Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.
    Kim MK; Park HS; Park CS; Min SJ; Albers FC; Yancey SW; Mayer B; Kwon N
    Korean J Intern Med; 2021 Mar; 36(2):362-370. PubMed ID: 32450626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
    Yancey SW; Bradford ES; Keene ON
    Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
    Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.